ArticleNature communications2026
Specialized aldo-keto reductases trigger complete degradation of mycotoxin deoxynivalenol.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on the toxicological characteristics and biodegradation of deoxynivalenol and its derivatives.Archives of toxicology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mycotoxin deoxynivalenol (DON) poses severe threats to human and animal well-being globally. Enzymatic degradation is the most effective way to eliminate DON toxicity, yet no catalytic process for complete degradation of DON has been uncovered. Here, we show that a metabolic pathway initiated by C3-epimerization and C8-reduction is responsible for complete degradation of DON in the DON-metabolizing bacterium Nocardioides sp. S5-5. Two horizontally transferred aldo-keto reductase genes, DONepi and DONrd, have evolved to orchestrate C3-epimerization and C8-reduction respectively. Notably, the octameric-structured DONepi alone catalyzes C3-epimerization of DON by steering the rigid-body rotation of the transient 3-keto intermediate for stereoinverting reduction. Moreover, DONrd can catalyze the C8-reduction of DON and its C3-epimerized product 3-epi-DON simultaneously to form C8-hydroxyl products, which facilitates the further degradation by a potential oxidase and other putative enzymes. DONepi expression in transgenic plants confers resistance to DON, representing potential for controlling mycotoxin contamination pre- and postharvest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.